Search results for: Value-Based Pricing
Filter search results
European Medicines Pricing and Reimbursement: Now and the Future
1 January 2007
…scenarios that might emerge in the next decade. – Martina Garau and Jorge Mestre-Ferrandiz in the Introduction Contents – Pricing and reimbursement policies in France: current and future trends; Pricing…
It Takes Two to Tango: When do Conditional Reimbursement Risk-Sharing Schemes Work for Both Parties?
1 December 2021
…of investment in evidence collection, matter. If the innovator expects to receive a value-based price that reflects the value of the health gain to the payer, then its evidence generation…
Making Outcome-based Payment a Reality in the NHS: Moving to the Next Phase
3 October 2019
…the benefits patients saw from treatment. The first phase also concluded that outcome-based payment could promote value for money in terms of NHS spending and support pharmaceutical innovation. These benefits…
HTA and Payment Mechanisms for New Drugs to Tackle AMR
23 September 2019
…but are traditionally not considered. These are transmission value, insurance value, diversity value, novel action value, enablement value, and spectrum value. Morton et al. (forthcoming) and Rothery et al. (2018)…
OHE’s AMR consultation response
21 November 2023
…learnings for establishing effective pull incentives in other jurisdictions. Notes 1 Value band 2: ‘critical value’ is defined as 70-79, so technically this dummy surpasses value band 2, but does…
Economics of Innovative Payment Models Compared with Single Pricing of Pharmaceuticals
1 July 2018
…prices below the value-based price. Erratum: 25/07/2018: Please note that this copy of the report (originally published 09/07/2018) has been updated to correct an error in Table 1 (p.9), whereby…
Breaking the European Deadlock: Part 3 – Revenue Guarantee and Subscription Models for New Antibiotics
16 January 2024
…& Steuten L., 2023. Incentivising New Antibiotics: Designing a Value-Based Delinked Pull Incentive Mechanism. OHE Contract Research. Available from https://www.ohe.org/publications/incentivising-new-antibiotics-designing-value-based-delinked-pull-incentive-antbiotics/ CCA (Council of Canadian Academies). (2023). Overcoming Resistance. Ottawa (ON): Expert…
Can Transparency Lower Prices and Improve Access to Pharmaceuticals? Five Questions We Think Matter a Lot
29 March 2019
…that of ECRI, a membership-based model whereby providers (and payers) can join and share the prices they get for medical devices and capital equipment in return for accessing performance, pricing…
HTA in Japan: Failing to Meet International Good Practice?
15 March 2019
…Analysis Guidelines for Cost-Effectiveness Assessment, Version 2 (draft) 12. 27. 2018 version. Kamae, I. Trial Implementation of Quasi Value-based Pricing for Pharmaceuticals and Medical Devices in Japan: Issues in Dispute….